{"id":"NCT02745392","sponsor":"Zosano Pharma Corporation","briefTitle":"Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine","officialTitle":"Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-06","primaryCompletion":"2017-01","completion":"2017-01","firstPosted":"2016-04-20","resultsPosted":"2018-02-14","lastUpdate":"2018-03-13"},"enrollment":365,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Migraine"],"interventions":[{"type":"DRUG","name":"ZP-Zolmitriptan","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"ZP-Zolmitriptan 1 mg","type":"EXPERIMENTAL"},{"label":"ZP-Zolmitriptan 1.9 mg","type":"EXPERIMENTAL"},{"label":"ZP-Zolmitriptan 3.8 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.","primaryOutcome":{"measure":"Proportion of Subjects With Pain Freedom","timeFrame":"2 hours","effectByArm":[{"arm":"Placebo","deltaMin":11,"sd":null},{"arm":"ZP-Zolmitriptan 1 mg","deltaMin":24,"sd":null},{"arm":"ZP-Zolmitriptan 1.9 mg","deltaMin":23,"sd":null},{"arm":"ZP-Zolmitriptan 3.8 mg","deltaMin":34,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":22},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["30698272","29022755"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":83},"commonTop":["Application site erythema","Application site bruise","Application site pain","Application site haemorrhage","Application site swelling"]}}